BIKTARVY Tablets (BIK) — Competitive Intelligence Brief

BIKTARVY Tablets (BIK) (BIKTARVY Tablets (BIK)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (INSTI + NRTI + NRTI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (INSTI + NRTI + NRTI) HIV reverse transcriptase, HIV integrase, HIV protease Infectious Disease / Virology Small molecule

Target snapshot

BIKTARVY Tablets (BIK) (BIKTARVY Tablets (BIK)) — ViiV Healthcare. BIKTARVY is a fixed-dose combination of three antiretroviral agents that inhibit HIV replication through complementary mechanisms: reverse transcriptase inhibition, integrase inhibition, and protease inhibition.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BIKTARVY Tablets (BIK) TARGET	BIKTARVY Tablets (BIK)	ViiV Healthcare	phase 3	Antiretroviral combination therapy (INSTI + NRTI + NRTI)	HIV reverse transcriptase, HIV integrase, HIV protease
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (INSTI + NRTI + NRTI) class)

1. ViiV Healthcare · 1 drug in this class